Regulatory & Compliance

Will Alyftrek Revolutionize CF Treatment in Europe?
Management & Regulatory Will Alyftrek Revolutionize CF Treatment in Europe?

In the realm of cystic fibrosis treatment, the recent European Commission approval of Vertex Pharmaceuticals' Alyftrek represents a significant leap forward. Ivan Kairatov, a biopharma expert deeply versed in technological and innovative advancements, provides his insights on this novel therapy and

Is Ziihera a Game-Changer for HER2-Positive Biliary Cancer?
Management & Regulatory Is Ziihera a Game-Changer for HER2-Positive Biliary Cancer?

Introducing Ivan Kairatov, a biopharma expert renowned for his insights into pharmaceutical technology and innovation, particularly in research and development. Today, we're delving into a groundbreaking moment for biliary tract cancer treatment with the conditional approval of Jazz

Can Lynozyfic Transform Multiple Myeloma Treatment?
Management & Regulatory Can Lynozyfic Transform Multiple Myeloma Treatment?

Ivan Kairatov is an esteemed biopharma expert with extensive knowledge in technological innovation within the industry, particularly in research and development. Today, we'll delve into the recent FDA approval of Regeneron's Lynozyfic for multiple myeloma and its implications for patients and

How Can AI in Healthcare Overcome Racial Biases?
Tech & Innovation How Can AI in Healthcare Overcome Racial Biases?

In the rapidly evolving landscape of healthcare and artificial intelligence, Ivan Kairatov stands out as a leading voice, particularly when it comes to understanding the complex intersection of bioethics, law, and technology in the biopharma industry. His extensive experience in research and

Lifestyle Changes Triumph Over Metformin in Diabetes Prevention
Research & Development Lifestyle Changes Triumph Over Metformin in Diabetes Prevention

The prevalence of diabetes presents an escalating health crisis with significant implications for individuals and healthcare systems globally. Among prediabetes patients, effective prevention strategies are vital to curb the increasing rates of Type 2 diabetes. Long-term studies underscore that

Are Patient-Friendly Drug Formulations the Future of Cancer Care?
Management & Regulatory Are Patient-Friendly Drug Formulations the Future of Cancer Care?

The field of cancer treatment has witnessed significant innovations, especially in the formulation of drugs designed to ease patient administration. The European Medicines Agency's endorsement of zanubrutinib tablets, Brukinsa's newer form, highlights an essential shift toward treatments that

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later